Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from Neuren Pharmaceuticals Limited ( (AU:NEU) ).
Neuren Pharmaceuticals Limited has announced an update regarding its ongoing on-market buy-back of ordinary fully paid securities. As of April 29, 2025, the company reported a total of 2,782,784 securities bought back before the previous day and an additional 67,662 securities bought back on the previous day. This buy-back initiative is part of the company’s strategy to manage its capital structure and potentially enhance shareholder value.
More about Neuren Pharmaceuticals Limited
Neuren Pharmaceuticals Limited operates in the pharmaceutical industry, focusing on the development of therapies for neurological disorders. The company is listed on the Australian Securities Exchange (ASX) under the code NEU.
YTD Price Performance: -6.56%
Average Trading Volume: 1,217
Technical Sentiment Signal: Hold
Current Market Cap: $926.4M
For a thorough assessment of NEU stock, go to TipRanks’ Stock Analysis page.